Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Georgia Capital impresses with Q4 performance

(Sharecast News) - Georgia-focused investment group Georgia Capital reported a big jump in profits in the fourth quarter after an "excellent" operating performance from across its portfolio. The value of its total portfolio rose 8.5% over the final four months of 2024 to GEL3.8bn (£1.1bn), with net asset value per share rising 15% to GEL95.95.

The company said the said the quarterly increase "reflects excellent underlying operating performances throughout the portfolio", with notable performances from Lion Finance Group (formerly Bank of Georgia Group), whose share price jumped 28.2%, as well as Georgia's Water Utility firm.

Revenues of all portfolio companies rose 8.8% over the period, while combined EBITDA surged 53.3%, with large portfolio companies growing sales by 18.2% and investment-stage firms seeing a 14.2% top-line increase.

Georgia Capital's net income amounted to GEL436m in the fourth quarter, up from GEL208m the year before, though full-year profits fell 43% to GEL350m.

The stock was 5.1% higher at 1,404p by 1206 GMT, having now risen more than 16% so far in 2025.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.